Zacks Research Issues Optimistic Forecast for IOVA Earnings

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) – Analysts at Zacks Research boosted their Q2 2026 earnings per share estimates for Iovance Biotherapeutics in a research report issued on Thursday, July 23rd. Zacks Research analyst Team now expects that the biotechnology company will post earnings of ($0.17) per share for the quarter, up from their previous forecast of ($0.18). The consensus estimate for Iovance Biotherapeutics’ current full-year earnings is ($0.60) per share. Zacks Research also issued estimates for Iovance Biotherapeutics’ Q3 2026 earnings at ($0.14) EPS, Q4 2026 earnings at ($0.12) EPS, FY2026 earnings at ($0.62) EPS, Q1 2027 earnings at ($0.10) EPS, Q3 2027 earnings at ($0.08) EPS, Q4 2027 earnings at ($0.07) EPS, FY2027 earnings at ($0.36) EPS, Q1 2028 earnings at ($0.05) EPS and FY2028 earnings at ($0.10) EPS.

IOVA has been the subject of a number of other reports. Chardan Capital cut their price objective on shares of Iovance Biotherapeutics from $16.00 to $14.00 and set a “buy” rating for the company in a report on Thursday, May 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Iovance Biotherapeutics in a report on Thursday, July 2nd. Five equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $8.43.

Iovance Biotherapeutics Trading Down 4.1%

NASDAQ IOVA opened at $4.70 on Monday. Iovance Biotherapeutics has a 12 month low of $1.76 and a 12 month high of $5.64. The stock has a market cap of $2.10 billion, a PE ratio of -4.95 and a beta of 0.70. The stock’s 50 day moving average is $4.27 and its 200 day moving average is $3.67.

Iovance Biotherapeutics (NASDAQ:IOVA) last released its earnings results on Thursday, May 7th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.19). The firm had revenue of $71.43 million during the quarter, compared to analysts’ expectations of $77.84 million. Iovance Biotherapeutics had a negative return on equity of 50.17% and a negative net margin of 123.92%.The firm’s revenue was up 44.9% on a year-over-year basis. During the same quarter last year, the business posted ($0.36) earnings per share.

Institutional Investors Weigh In On Iovance Biotherapeutics

Several large investors have recently made changes to their positions in the company. State Street Corp boosted its position in shares of Iovance Biotherapeutics by 51.5% during the 4th quarter. State Street Corp now owns 20,161,445 shares of the biotechnology company’s stock valued at $55,041,000 after acquiring an additional 6,851,486 shares during the last quarter. Palo Alto Investors LP grew its holdings in shares of Iovance Biotherapeutics by 122.1% in the third quarter. Palo Alto Investors LP now owns 7,618,132 shares of the biotechnology company’s stock valued at $16,531,000 after purchasing an additional 4,188,803 shares in the last quarter. HRT Financial LP increased its position in Iovance Biotherapeutics by 1,078.3% in the fourth quarter. HRT Financial LP now owns 4,356,010 shares of the biotechnology company’s stock worth $11,891,000 after purchasing an additional 3,986,314 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Iovance Biotherapeutics by 202.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,777,344 shares of the biotechnology company’s stock worth $19,239,000 after purchasing an additional 3,869,617 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in Iovance Biotherapeutics by 13.1% during the fourth quarter. Vanguard Group Inc. now owns 27,207,079 shares of the biotechnology company’s stock valued at $74,275,000 after purchasing an additional 3,148,096 shares in the last quarter. 77.03% of the stock is owned by institutional investors.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.